News
-
-
PRESS RELEASE
Gladstone Capital Announces Monthly Cash Distributions for October, November and December 2025 and Conference Call Date
Gladstone Capital Corporation (Nasdaq:GLAD) declares monthly cash distributions for October, November, December 2025. Adjusts dividend rate due to market conditions. Plans earnings report for Q4 2025 -
-
PRESS RELEASE
EQS-Adhoc: HomeToGo SE: HomeToGo issues updated FY/25 guidance following Interhome closing and provides an estimate of IFRS Revenues of c. €400M and Adjusted EBITDA of c. €40M for 2025 on a pro-forma basis
HomeToGo SE updates FY/25 guidance post Interhome acquisition, projects IFRS Revenues of c. €400M & Adjusted EBITDA of c. €40M for 2025 on pro-forma basis. Details on financial impacts from transaction closing -
-
PRESS RELEASE
Gladstone Commercial Corporation Announces Monthly Cash Distributions for October, November and December 2025 and Earnings Release and Conference Call Dates for its Third Quarter Ended September 30, 2025
Gladstone Commercial Corp announces cash distributions for Oct-Dec 2025 & Q3 earnings report. Detailed breakdown of distribution per stock type provided -
PRESS RELEASE
Gladstone Land Announces Monthly Cash Distributions for October, November and December 2025 and Earnings Release and Conference Call Dates for the Third Quarter Ended September 30, 2025
Gladstone Land Corporation declares monthly cash distributions for common stock and preferred stocks for October to December 2025. Earnings announcement scheduled for November 5, 2025 -
PRESS RELEASE
Gladstone Investment Announces Monthly Cash Distributions for October, November and December 2025, and Earnings Release and Conference Call Dates for the Second Fiscal Quarter
Gladstone Investment Corporation (Nasdaq: GAIN) declares $0.08 per share monthly cash distributions for October, November, and December 2025. Earnings report for Q2 2025 to be released on November 4, 2025 -
-
PRESS RELEASE
Inventiva annonce la mise en place d’un nouveau programme « At-The-Market » (ATM)
Inventiva lance un nouveau programme de financement At-the-Market (ATM) pour une levée de fonds jusqu'c 100 millions de dollars, dans le but de soutenir le développement de thérapies contre la stéatohépatite